CD9-HM196-100μg / 询价
CD9-HM196-500μg / 询价
CD9-HM196-500μgx2 / 询价
Human CD96/TACTILE Protein
Recombinant Human CD96/TACTILE Protein is expressed from HEK293 with His tag at the C-Terminus.It contains Val22-Met503 [Accession | P40200-2].
The protein has a predicted MW of 54.7 kDa. Due to glycosylation, the protein migrates to 115-130 kDa based on Bis-Tris PAGE result.
> 95% as determined by Bis-Tris PAGE
> 95% as determined by HPLC
Less than 1EU per ug by the LAL method.
Lyophilized from 0.22μm filtered solution in PBS (pH 7.4). Normally 8% trehalose is added as protectant before lyophilization.
Centrifuge the tube before opening. Reconstituting to a concentration more than 100 μg/ml is recommended. Dissolve the lyophilized protein in distilled water.
-20 to -80°C for 12 months as supplied from date of receipt.
-80°C for 3 months after reconstitution.
Recommend to aliquot the protein into smaller quantities for optimal storage. Please minimize freeze-thaw cycles.
Human CD96 on Bis-Tris PAGE under reduced condition. The purity is greater than 95%.
The purity of Human CD96 is greater than 95% as determined by SEC-HPLC.
Immobilized Anti-CD96 Antibody, hFc Tag at 1μg/ml (100μl/well) on the plate. Dose response curve for Human CD96, His Tag with the EC50 of 28.8ng/ml determined by ELISA (QC Test).
Human CD155, hFc Tag captured on CM5 Chip via Protein A can bind Human CD96, His Tag with an affinity constant of 0.958 μM as determined in SPR assay (Biacore T200).
The receptors CD96 and TIGIT are expressed on the surface of T and natural killer (NK) cells, and recent studies suggest both play important inhibitory roles in immune function. CD96 has been shown to modulate immune cell activity in mice, with Cd96-/- mice displaying hypersensitive NK-cell responses to immune challenge and significant tumor resistance. The counterbalance between the putative inhibitory CD96 and TIGIT receptors and the activating receptor, CD226, offers unique strategies for immuno-oncology drug development.
CD96 molecule; CD96; DKFZp667E2122; TACTILE
(1) Blake SJ, Dougall WC, Miles JJ, Teng MW, Smyth MJ. Molecular Pathways: Targeting CD96 and TIGIT for Cancer Immunotherapy. Clin Cancer Res. 2016 Nov 1;22(21):5183-5188. doi: 10.1158/1078-0432.CCR-16-0933. Epub 2016 Sep 12. PMID: 27620276.
